CD4+ T cell enumeration is used to determine eligibility for antiretroviral therapy (ART) and to monitor the immune status of HIV-positive patients; however, many patients do not have access to this essential diagnostic test. Introducing point of care (POC) testing may improve access. We have evaluated Alere's PIMA TM , one such POC device, against conventional CD4+ testing platforms to determine its performance and validity for use in Kenya. In our hands, Alere PIMA TM had a coefficient of variability of 10.3% and of repeatability of 175.6 cells/ml. It differed from both the BD FACSCalibur TM (r 2 = 0.762, mean bias 264.8 cells/ml), and the BD FACSCount TM (r 2 = 0.874, mean bias 7.8 cells/ml). When compared to the FACSCalibur TM at a cutoff of 350 cells/ml, it had a sensitivity of 89.6% and a specificity of 86.7% in those aged 5 years and over (Kw = 0.7566). With the BD FACSCount TM , it had a sensitivity of 79.4% and a specificity of 83.4% in those aged 5 years and over (Kw = 0.7790). The device also differed from PARTEC Cyflow TM (r 2 = 0.781, mean bias 224.2 cells/ml) and GUAVA TM (r 2 = 0.658, mean bias 20.3 cells/ml) platforms, which are used in some facilities in Kenya. We conclude that with refinement, Alere PIMA TM technology has potential benefits for HIV-positive patients. This study highlights the difficulty in selecting the most appropriate reference technology for technical evaluations.
Introduction
CD4+ T cell quantification by flow cytometry is considered accurate, precise and reproducible [1, 2] . A CD4+ T cell count is positively linked to long-term survival rates and indicates the level of immunosuppression [3] [4] [5] . During testing, patients older than five years of age are given an absolute CD4+ T cell count, which is determined as CD4+ cells/mL of blood. For patients five years old and younger, it is necessary to measure the percentage of CD4+ T cells among all lymphocytes [6] .
Despite the fact that CD4+ T cell enumeration is essential in the initiation of antiretroviral therapy and the monitoring of care and treatment in Kenya, many HIV-positive patients still do not have reliable access to these services [7, 8] . CD4 testing is often only available at centralized laboratories with significant infrastructure investments and highly skilled laboratory technicians [7] . Laboratory networking has improved access somewhat, but sample transportation networks are still so poor that many patients are unable to access adequate and necessary CD4 testing.
Currently, CD4 testing using flow cytometry technology is available in many central and regional laboratories in Kenya using BD FACSCount TM or BD FACSCalibur TM (Becton Dickinson, Franklin Lakes, NJ, USA), PARTEC Cyflow TM (Partec GmbH, Munster, Germany), or GUAVA TM (EMD Millipore Corporation, Billerica, MA, USA) platforms. Unfortunately, this combination of technologies is insufficient to provide CD4 testing to all patients who need them. Long turn-around times for tests sent to central laboratories delay clinical decisions and put a considerable burden on patients. Conventional CD4 testing requires samples be transported in complicated and inefficient sample transportation networks and over long, rough roads. These transportation networks are limited and expensive, and are often compounded by the difficulties of short sample stability.
Fortunately, high quality Point-Of-Care (POC) diagnostic technologies are promising solutions to critical CD4 testing needs in areas without existing laboratory capacity or easy access to conventional CD4 testing laboratories [9] [10] [11] [12] [13] . For example, HIV rapid diagnostic tests have increased patient access to HIV diagnosis in the last decade [14] . POC diagnostic technologies offer several advantages in that they are generally small, robust, relatively low cost, require little infrastructure, and require minimum technical skills. Additionally, replacement devices can be sent to a site immediately to sidestep POC device downtime. CD4 POC technologies can ease human resource capacity shortages and testing backlogs at central laboratories by diverting samples that are customarily referred. Most importantly, CD4 POC testing can allow doctors to make treatment decisions faster and achieve significant improvements in patient health outcomes.
POC 
Study Participants
All patients attending the selected facilities for HIV treatment and care were eligible for this study. Only patients who provided written informed consent were enrolled in the study. In the case of children below 18 years of age, a parent or legal guardian made the decision regarding participation and gave written informed consent. A total of 1,549 patients were recruited from the nine study sites. Data on gender was available for 1,482 patients: 984 (66.3%) were female, while 498 (33.7%) were male. The median age was 36 years (range 1-75 years old) with an approximately normal distribution; 68 patients were aged 18 years or less. At least 49.7% of the patients were on antiretroviral therapy. Qualified and trained laboratory technicians conducted all tests.
Study Design
In this methods comparison study, venous and capillary blood specimens were collected consecutively from all eligible patients presenting at the health clinics included in the study who agreed to participate in the study through informed consent. Demographic data, CD4+ T cell count, date of clinic visit and antiretroviral (ARV) use were all recorded in a structured questionnaire and entered into an Access database. The data from all testing sites was similarly uploaded remotely to a central server. This study was reviewed and approved by the Kenya Medical Research Institute Ethical Review Committee (Protocol No. SSC1880). For all patients under the age of 18 years, a parent or guardian gave written informed consent. Children between the ages of 13 and 17 years also gave assent. Patients were only provided with CD4+ T cell results obtained from the conventional CD4 testing platforms for further clinical management. Additionally, all technologists are trained annually in good laboratory practice, immunophenotyping for flow cytometry, reverse pipetting, biosafety and good phlebotomy practice. All devices used in this study passed EQA prior to study commencement and all staff conducting testing were trained to perform routine IQA. Control cartridges (both high and low) were run on the PIMA device every morning before tests. PIMA devices reporting errors were not used for this work.
Laboratory Procedures

Data Analysis
The results of the evaluation were analyzed using standard statistical methods. The absolute CD4+ T Cell counts derived from Alere PIMA TM device were compared with those derived from existing technologies by calculating the coefficient of determination (r 2 ) and conducting regression analysis using STATA v. 12 for Mac OSX. To determine interchangeability between the device and exisiting platforms, Bland-Altman analysis and Lin's concordance correlation coefficient (rhoC) were used. For the former analysis, the bias was defined as the mean difference between two methods. The limits of agreement (LoA) between the methods compared were calculated as the mean 61.96 Standard Deviations (SD) of the differences between the results obtained. Confidence intervals for bias and for limits of agreement were calculated using formulae previously described by Bland and Altman [20] . The x axis on each Bland-Altman plot was the average value of the two methods while the y axis was the difference between the two methods. For Lin's concordance correlation, the coefficient of determination was derived by squaring the coefficient of determination r and was used to quantify the percentage variation of the dependent variable that could be attributed to the variations in the independent variable of the correlation equation. Both the coefficient of variation and the coefficient of repeatability were also calculated for the Alere PIMA TM device. The coefficient of variation was used to define the instrument precision and was calculated as the (standard deviation6100)/mean of a set of repeated measurements on one sample using one instrument. The coefficient of repeatability, a measure of test-retest precision was defined as the variation in duplicate measurements for several samples, taken by a single technician using the same instrument under the same conditions. It was calculated as 1.96 times the standard deviation of the differences between the two measurements. To determine the effect of the platform under evaluation on eligibility of patients for antiretroviral therapy, Cohen's weighted kappa statistic (Kw) was used.
Results
Since we evaluated Alere PIMA TM in the context of existing technologies. The coefficients of repeatability and the mean bias When whole blood was compared with capillary blood from the same patient on the same Alere PIMA TM machine, the results were as follows: The mean bias was 27.7 cells/ml (95% LoA 2236.2, 220.7). The coefficient of determination (r 2 ) was 0.821 (Figs. 3a. & 3b. ).
The precision of the Alere PIMA TM platform was determined by running the same sample 16 times using cartridges from the same batch. The mean CD4 count from that sample was 275.9 cells/ml, with a standard deviation of 28.5 cells/ml. The coefficient of variation was therefore 10.3%. To understand the reproducibility of results using the Alere PIMA TM platform, All 211 patients enrolled in the study from Alupe Sub District Hospital provided blood in EDTA tubes each of which was tested twice, on the same Alere PIMA TM device. The mean difference between the tests was 6.9 cells/ml, with a coefficient of repeatability of 175.6 cells/ml.
In comparison, blood collected from 197 patients at Alupe Sub District Hospital was tested using the BD FACSCount TM platform to determine the coefficient of repeatability. The mean difference on the device was 2.2 cells/ml, and the coefficient of repeatability was 66.0 cells/ml.
In Kenya, the Ministry of Health has expressed a desire to identify one point of care platform that can be used interchange- Table 1 . Summary of coefficients of determination and mean bias for all comparisons between instruments. PIMA TM ably with all the existing technologies. To that end, we compared the Alere PIMA TM to additional CD4 testing technologies to determine interchangeability with various other platforms.
In a comparison using capillary blood for Alere PIMA TM and whole blood for PARTEC Cyflow TM comparison, the coefficient of determination (r 2 ) was 0.852 while the mean bias between these two platforms was 210.0 cells/ml (95% LoA 2261.4, 241.4, n = 162). When whole blood specimens (n = 407; 166 patient samples from Andersen Medical Centre and 241 patient samples from University of Nairobi Immunology Department) were used for both platforms the coefficient of determination (r 2 ) was 0.781, while the mean bias between these two CD4 enumeration technologies was 224.2 (95% CI 2277.6-229.3) cells/ml.
Alere PIMA TM was assessed against the GUAVA TM platform with the former using capillary blood samples and the latter whole blood samples in 176 patients (165 from ACK St Luke's Hospital Kaloleni and 11 from Andersen Medical Centre). In this exercise, the coefficient of determination was determined to be 0.681. The mean bias between the machines was 23.9 (95% LoA 2329.6, 281.9). When whole blood was used in this comparison for both platforms, the coefficient of determination (r 2 ) was 0.658. The mean difference was 20.3 (95% LoA 2315.0, 315.6, n = 191) cells/ml.
Finally, we assessed whether the sample type might affect the CD4 test result on the Alere PIMA TM platform. 840 samples of each type were compared. r 2 was 0.821. The mean bias between whole blood and capillary blood samples when tested with the PIMA device was 7.7 cells/ml (95% LoA 2220.7, 236.1).
In Kenya, HIV+ patients are eligible for ART initiation when their CD4+ T cell count falls to or below 350 cells/ml. We, therefore, used this threshold to determine the sensitivity and specificity of PIMA TM using either the FACSCalibur TM (which is the gold standard) or the BD FACSCount TM (which is the most commonly available platform).
When compared to the FACSCalibur TM , Alere PIMA TM had a sensitivity of 89.6% and a specificity of 86.7% in those aged 5 years and over (n = 389, Kw = 0.7566 ). On the other hand, when compared with the BD FACSCount TM , Alere PIMA TM had a sensitivity of 79.4% and a specificity of 83.4% in those aged 5 years and over (n = 813, Kw = 0.7790; Table 2 ).
When we lowered the threshold to 200 cells/ml, the sensitivity of Alere PIMA TM was 86.7% while the specificity was 94.12% when compared with FACSCalibur TM (n = 389 people aged 5 or older, Kw = 0.7619). Against the FACSCount, the sensitivity and specificity were 83.0% and 98.2% respectively (n = 813, Kw = 0.8422, Table 3 ).
To contextualize these findings, we compared patient eligibility for ART using BD FACSCount TM with BD FACSCalibur as the gold standard at a threshold of 350 cells/ml. The BD FACSCount TM had a sensitivity of 93.8% and a specificity of 82.4% in those aged 5 years or older (n = 305, Kw = 0.7528). When this threshold was dropped to 200 cells/ml, the sensitivity and specificity became 94.4% and 93.2% respectively (n = 305, Kw = 0.8040).
Finally, we compared the ART eligibility classification rates between the Alere Pima TM and two additional CD4 testing technologies at a threshold of 350 cells/cells/ml (Table 3) . With GUAVA TM , Kw was 0.7630 (n = 189) while for PARTEC Cyflow TM , it was 0.7875 (n = 400).
Discussion
By the end of 2011, Kenya had approximately 500,000 adults and 40,000 children on ART and, therefore, in need of routine immunological and virological monitoring. HIV testing and ART are available at thousands of health care facilities nationwide, but CD4+ T cell enumeration for ART initiation eligibility and immunological monitoring is, unfortunately, available in only about 200 out of the more than 8000 health care facilities. Laboratory sample referral networking is well established in a few areas, but for a majority of patients, access to CD4 testing is a challenge. In fact, although health care facilities are able to provide ART and monitor clinical outcomes and the side effects of medication, they are often unable to routinely initiate patients on ART due to the inability to access CD4+ T cell enumeration services.
Many of the existing technologies are expensive and not readily accessible. If a new point of care technology can provide reliable and accurate results, and is interchangeable with existing platforms, then it can be used not only to reduce costs and improve access but also to standardize the testing service. The Kenya Ministry of Health believes that it can benefit from economies of scale in a standardized test environment.
It should be pointed out that, by their very nature, point of care tests may not provide the same sensitivity, specificity and accuracy as the ''gold standard'' reference tests. The trade off is that they can provide access to a CD4 T Cell enumeration service where none exists. To set the pace for this evaluation, we sought to determine whether the commonest CD4 enumeration platform (BD FACSCount TM ) in Kenya is interchangeable with the gold standard (BD FACSCalibur TM ). The coefficient of determination suggested that the agreement between the two platforms was less than perfect. In fact, with a mean bias of 76.5 cells/ml, these platforms are not interchangeable. Differences between the two platforms have been reported in the literature, and may be partially explained by the fact that the BD FACSCalibur TM allows for some subjectivity when laboratory technicians manually gate the CD4+ T cell population.
These differences are clinically important regardless of whether the threshold for ART initiation is set at 350 cells/ml or at 200 cells/ml. If the BD FACSCalibur TM is to be considered the most accurate CD4+ T cell enumeration platform available in Kenya, then our data suggests significant misclassification of patients by the BD FACSCount TM . Many patients who are currently on ART due to their CD4 result using the BD FACSCount TM would not have been initiated on ART when tested with the BD FACSCalibur TM . We recommend that patients remain faithful to one platform during their care. When evaluated for precision, Alere PIMA TM gave a coefficient of variability of 10.3%. This level of precision has been reported before [21] . In our opinion, this precision is less than desirable, and much lower than that reported for either the BD FACSCalibur TM or the BD FACSCount TM [22] . There was minimal bias using either capillary blood or whole blood samples on Alere PIMA TM . This is a positive finding, suggesting that this platform can be used in a variety of settings. Additional, the reproducibility of results using whole blood on the same Alere PIMA TM platform was very high, another encouraging finding.
Previous studies have reported that the Alere PIMA TM device is comparable and interchangeable with the existing CD4 enumeration platforms [17, 18, 21, [23] [24] [25] [26] . In our hands, we found no such thing. 
Conclusion
We conclude that with additional refinement, the potential benefits of the Alere PIMA TM technology for HIV-positive patients cannot be exaggerated. It can expand access to CD4 testing, particularly in rural settings whose needs are currently unmet by existing laboratory testing networks. Additionally, this study highlights the difficulty in selecting the most appropriate 'gold standard' or reference technology for technical evaluations. 
